Ignite Creation Date:
2024-05-05 @ 10:47 PM
Last Modification Date:
2024-10-26 @ 10:24 AM
Study NCT ID:
NCT01186744
Status:
COMPLETED
Last Update Posted:
2018-12-26
First Post:
2010-08-20
Brief Title:
A Study To Evaluate The Effects And Safety Of Treatment Treatment Withdrawal Followed By Re-Treatment With CP-690550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 3 Multi-Site Randomized Mixed-Blind Parallel-Group Treatment Withdrawal And Re-Treatment Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status:
COMPLETED
Status Verified Date:
2018-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objectives of the study are to 1 compare the efficacy responses of CP 690550 5 mg BID and 10 mg BID versus placebo following 24 weeks of CP 690550 treatment and subsequent withdrawal of active treatment at various timepoints during the 16 week double blind active or placebo treatment period 2 evaluate the regain of efficacy responses of CP 690550 5 mg BID and 10 mg BID following 4 -16 weeks of CP 690550 treatment withdrawal and subsequent re treatment and 3 evaluate the safety and tolerability of CP 690550 5 mg BID and 10 mg BID in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None